Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.

Phenytoin, a medication, can cause hair loss and trigger a condition similar to lupus.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study reports that hair loss may be a rare side effect of levetiracetam in epilepsy patients and appears reversible upon dose reduction or cessation.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This study found that in Withdrawal Seizure-Prone mice, ethanol withdrawal decreased the sensitivity of GABA A receptors to GABAergic neurosteroids in certain areas of the brain.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

In this study conducted at Shafa Hospital, Kerman, Iran, 3.5% of patients using sodium valproate as an antiepileptic experienced hair loss and curling over ten years.

This case report described a probable case of acute liver injury associated with high-dose S. repens, highlighting the safety concerns of self-medicating with herbal supplements like saw palmetto.

This article discusses pharmacologic treatments for male sexual offenders, focusing on reducing sexual drive through nonhormonal or hormonal means, but it reports no new clinical results.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study suggests that inhibiting 5α-reductase activity alone, particularly with the type 1 inhibitor MK386, may not effectively reduce sebocyte activity or improve acne.

In this study, newly diagnosed women with mycosis fungoides or Sézary syndrome and those with alopecia experienced significantly poorer health-related quality of life.

This narrative account, reported by C&EN, describes how Houston's use of a hormone-related hair loss treatment may have triggered unexpected panic attacks, contributing to ongoing mental health challenges, and highlights broader issues with mental health disorders that resist traditional treatments.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This article discusses historical serendipitous discoveries in science and medicine but provides no new research findings.

This case report reviews the management of Rowell syndrome in a patient initially diagnosed with Rhupus syndrome and highlights their development of erythema multiforme after certain medications.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.